On November 29, 2021 Vyant Bio, Inc. ("Vyant Bio", the "Company") (Nasdaq: VYNT), an emerging global drug discovery company, reported that it is rapidly identifying small and large molecule therapeutics to treat central nervous system (CNS) and oncology-related diseases (Press release, Vyant Bio, NOV 29, 2021, View Source [SID1234596206]). Today, Vyant Bio announced that it will be participating in The Benchmark Company Discovery One-on-One Investor Conference. The event is being held virtually on Thursday, December 2, 2021.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference Date: December 2, 2021 (Thursday)
1:1 Availability: 8:00am-4pmET
Vyant Bio’s Chief Executive Officer, Jay Roberts, will be discussing key highlights from the Third Quarter 2021, the recent addition of Chief Scientific Officer – Dr. Robert Fremeau, and the business and strategic outlook for the remainder of 2021 and into 2022.

If you are an investor and would like to schedule a one-on-one meeting with Vyant Bio during the Discovery One-on-One Investor Conference, please contact your Benchmark representative.

Vyant Bio will also be available for virtual outside 1:1 meetings after The Benchmark Company Discovery One-on-One Investor Conference. Please contact Jennifer K. Zimmons, Ph.D. at [email protected] or +1 917.214.3514 for scheduling.